The U.S. Army Contracting Command at Aberdeen Proving Ground, Maryland, awarded Sherpa 6 Inc. of Littleton, Colorado a $239,649,259 firm-fixed-price contract on June 4, 2026, covering critical technologies in chemical and biological detection and Soldier protection. As reported by ClearanceJobs, the award — contract number W912CG-26-D-A001 — was issued as a sole-source Small Business Innovation Research Phase III action, with only one offer received. The period of performance runs through June 3, 2031, giving the Army five years to draw down task orders against the contract ceiling.
What SBIR Phase III Actually Means
For contractors unfamiliar with SBIR mechanics, the Phase III designation is more than a label — it is a statutory authority that fundamentally changes the competitive landscape. Under 15 U.S.C. § 638, SBIR Phase III work refers to the commercialization of technologies developed during Phases I and II using non-SBIR federal funding. The critical implication: Phase III awards are explicitly exempt from the normal full-and-open competition requirements that govern most federal procurements.
In practical terms, an agency that funded a small business through Phase I feasibility studies and Phase II prototype development can follow that investment directly into a Phase III production or deployment contract without re-competing the underlying technology. The rationale is straightforward — the government already paid for the research that produced the solution; re-competing it would invite proposals from firms that did not bear the R&D risk and could undercut the innovator on price while leveraging the government-funded intellectual foundation.
This is precisely what happened here. Sherpa 6 presumably conducted earlier-phase SBIR work on chemical and biological detection technologies for the Army, establishing a prior performance record and a technical baseline that qualified the company for a sole-source follow-on. Because Phase III authority is grounded in statute rather than FAR Part 6 sole-source exceptions, contracting officers have broad latitude to structure these awards without the justifications and approvals required for a standard J&A. That statutory backing is why $239M can flow to a single small business through a single award action.
Scope and Structure of the Contract
The contract covers what the Army describes as "Provide critical technologies in chemical and biological detection and Soldier protection" That language maps directly to the Army's Chemical, Biological, Radiological, and Nuclear (CBRN) defense mission — specifically, the detection and characterization of threat agents in the field and the protective measures that shield individual Soldiers from exposure.
The firm-fixed-price structure is notable at this contract value. FFP shifts performance risk to the contractor, which is appropriate for mature technologies transitioning out of R&D and into production or fielding. It also signals that the Army and Sherpa 6 have sufficient cost visibility from prior Phase I and II work to set a ceiling with confidence. The five-year period of performance — June 2026 through June 2031 — gives the Army flexibility to sequence deliveries and upgrades without returning to market, while giving Sherpa 6 a stable revenue horizon to plan workforce and supply chain accordingly.
Only one offer was received, which is consistent with a sole-source SBIR Phase III action. Unlike a sole-source justification under FAR 6.302, a Phase III award does not require the agency to solicit even informally before proceeding; the statutory authority itself constitutes the competition finding. The single-offer notation in the contract announcement is essentially procedural — it confirms the action was properly structured rather than indicating a failed competition.
CBRN Defense Context
Chemical and biological detection is one of the Army's highest-priority capability gaps. Modern threat actors — state and non-state alike — have demonstrated both the intent and the technical means to deploy chemical and biological agents against military forces and civilian populations. The Army's response has been to accelerate investment in detection systems that can identify threat agents faster, at lower concentrations, and with fewer false positives than legacy equipment.
SBIR has been a preferred vehicle for that acceleration because it allows the Army to fund high-risk, early-stage technology development at the small business level, where speed and specialization often outpace what large prime contractors can deliver on contract. When a Phase I or Phase II effort produces a viable capability, the Phase III pathway lets the Army scale it quickly without the multi-year procurement cycle that a new program of record would require.
At nearly $240 million, this award is among the largest SBIR Phase III contracts publicly reported in 2026. It reflects the Army's willingness to commit significant production funding to a small business when the technology and the track record justify it.
What It Means for Contractors
For government contractors watching this award, there are several practical takeaways.
First, SBIR Phase III is a legitimate pathway to large-dollar sole-source contracts, not just a vehicle for small pilot programs. Any small business currently holding Phase I or Phase II awards in priority capability areas — CBRN, autonomy, directed energy, electronic warfare — should be explicitly planning the Phase III transition with their program office counterparts. That conversation should start before Phase II concludes, not after.
Second, the firm-fixed-price structure at this scale is a signal about what the Army expects from a Phase III transition: production-ready technology with defensible cost estimates, not continued R&D. Contractors pursuing Phase III follow-ons should invest in cost accounting rigor and manufacturing readiness assessments during Phase II, so that the FFP negotiation is grounded in data rather than guesswork.
Third, the five-year ceiling contract structure — with a June 2031 end date — leaves room for task order competition under the umbrella award if the Army chooses to structure it that way. Prime contractors and subcontractors in the CBRN detection supply chain should monitor Sherpa 6's teaming and subcontracting activity over the contract period, as opportunities to support delivery may emerge through the company's own procurement channels.
Finally, this award demonstrates that the Army Contracting Command at Aberdeen Proving Ground is actively using Phase III authority for large-scale CBRN acquisitions. Contractors with relevant capabilities — detection sensors, protective equipment, integration software, logistics support — who are not currently engaged with ACC-APG's CBRN portfolio should evaluate whether a Phase I proposal or a direct approach to program offices makes sense given their technology readiness level.
